Provided by Tiger Trade Technology Pte. Ltd.

ProQR Therapeutics NV

2.34
+0.07003.08%
Post-market: 2.340.00000.00%19:54 EDT
Volume:725.82K
Turnover:1.70M
Market Cap:330.22M
PE:-5.11
High:2.37
Open:2.28
Low:2.26
Close:2.27
52wk High:3.10
52wk Low:1.33
Shares:141.12M
Float Shares:101.18M
Volume Ratio:0.57
T/O Rate:0.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4578
EPS(LYR):-0.4702
ROE:-57.40%
ROA:-19.76%
PB:3.56
PE(LYR):-4.98

Loading ...

ProQR Therapeutics (PRQR) Stock Rises On Revenue Surge As Losses Ease

Simply Wall St.
·
Aug 15

Cantor Fitzgerald Keeps Their Buy Rating on ProQR (PRQR)

TIPRANKS
·
Aug 14

ProQR Therapeutics NV Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

ProQR Q2 Revenue More than Doubles

Reuters
·
Aug 13

ProQR Q2 FY26 Net Loss Narrows to EUR 8.7 Million

Reuters
·
Aug 13

ProQR Therapeutics Q2 Basic EPS EUR -0.08

THOMSON REUTERS
·
Aug 13

ProQR Therapeutics Q2 Revenue EUR 8.759 Million VS. Ibes Estimate EUR 4.58 Million

THOMSON REUTERS
·
Aug 13

ProQR Therapeutics NV Expected to Post a Loss of 11 Cents a Share - Earnings Preview

Reuters
·
Aug 11

ProQR CEO Daniel Anton De Boer Acquires 200,000 Shares for $353,960

Reuters
·
Aug 04

ProQR Therapeutics NV Expected to Post a Loss of 11 Cents a Share - Earnings Preview

Reuters
·
Aug 03

Proqr Therapeutics Director Bart Filius Buys $257,925 of Common Shares

Reuters
·
Jul 21

Proqr CEO Daniel Anton De Boer Buys 150,000 Shares for $261,000

Reuters
·
Jul 13

Proqr CEO Daniel Anton De Boer Buys $238,500 in Ordinary Shares

Reuters
·
Jul 09

ProQR Registers Shares for Resale by Investor

MT Newswires Live
·
Jul 07

Proqr Therapeutics Nv - Files to Register Resale of up to 3.03 Mln Ordinary Shares - SEC Filing

THOMSON REUTERS
·
Jul 07

Oppenheimer Reaffirms Their Buy Rating on ProQR (PRQR)

TIPRANKS
·
Jul 06

Proqr Director Bart Filius Acquires 150,000 Shares for $231,000

Reuters
·
Jul 01

Analysts’ Top Healthcare Picks: ProQR (PRQR), Neurogene (NGNE)

TIPRANKS
·
Jun 29

Proqr Sells 5,100,780 Shares to Lilly in $9.2 Million Private Placement at $1.81 Each

Reuters
·
Jun 26

ProQR Therapeutics Says Phase 1 Trial of Liver Drug Candidate Meets Primary Endpoint

MT Newswires Live
·
Jun 25